OPN1SW and atherosclerosis: These anti-atherogenic and anti-inflammatory effects were reversed by the presence of selective CB2R antagonist SR44628, thus demonstrating the protective role of CB2R activation in regulating foam cell formation and inflammation as a potential target for treating atherosclerosis through BCP.